摘要
目的探讨氨氯地平联合厄贝沙坦对血液透析(HD)合并高血压患者血压水平及肾功能的影响。方法选取2015年1月至2016年12月我院60例HD合并高血压患者,按随机数字表法分为两组,每组各30例。对照组采用氨氯地平,观察组采用氨氯地平、厄贝沙坦治疗。比较两组血压水平[舒张压(DBP)、收缩压(SBP)]、肾功能[血尿素氮(BUN)、血肌酐(SCr)]及不良反应。结果两组治疗前DBP、SBP及治疗前后SCr、BUN水平对比,无统计学差异(P>0.05);治疗后观察组DBP、SBP低于对照组(P<0.05);治疗后观察组、对照组SCr、BUN均低于治疗前(P<0.05);两组不良反应发生率无统计学差异(P>0.05)。结论HD合并高血压患者采用氨氯地平、厄贝沙坦联合治疗有利于提升血压控制效果,改善肾功能,且未增加药物副作用,临床应用安全可靠。
Objective This paper aims to investigate the effect of amlodipine combined with irbesartan on blood pressure and renal function in hemodialysis(HD)patients with hypertension.Methods From January 2015 to December 2016,60 HD patients with hypertension were randomly divided into two groups,30 cases in each group.The control group was treated with amlodipine,and the observation group was treated with amlodipine and irbesartan.The blood pressure level[diastolic blood pressure(DBP),systolic blood pressure(SBP)],renal function[blood urea nitrogen(BUN),serum creatinine(SCr)]and adverse reactions were compared between the two groups.Results There was no significant difference in DBP,SBP,SCr and BUN levels between the two groups before and after treatment(P>0.05);After treatment,DBP and SBP in the observation group were lower than those in the control group(P<0.05);After treatment,SCr and BUN of the two groups were lower than those before treatment(P<0.05);There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Amlodipine combined with irbesartan in the treatment of HD patients with hypertension can improve the effect of blood pressure control and renal function without increasing drug side-effects which is safe and reliable in clinical application.
出处
《透析与人工器官》
2017年第1期13-14,16,共3页
Chinese Journal of Dialysis and Artificial Organs
关键词
血液透析
高血压
氨氯地平
厄贝沙坦
血压
肾功能
hemodialysis
hypertension
amlodipine
irbesartan
blood pressure
renal function
